Program
flonoltinib
Also written as “Flonoltinib 75mg”, “Flonoltinib 100mg” and “flonoltinib 25mg”.
Its studies are mostly in Myeloproliferative Disorders · Polycythemia Vera, led by 2 companies.
Drug pageFlonoltinib: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chengdu Zenitar Biomedical Technologyits history only | 64 open or running | phase 3since Dec 19, 2025 | Nov 29, 2021 | Dec 30, 2026phase 1 · NCT07768111 |
| Guizhou Bailing Group Pharmaceutical | 10 open or running | phase 1since Aug 12, 2021 | Aug 12, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Guizhou Bailing Group Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 12, 2021First study: phase 1 study in Myeloproliferative DisordersFirst studyNCT05115344
TargetBeta
“Flonoltinib Maleate (FM), a triple target inhibitor of JAK2/FLT3/CDK6, has the potential to inhibit JAK2 signaling pathway activity and treat bone marrow proliferative tumors.”study text, by rule · the study
Studies
The one study Guizhou Bailing Group Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05115344Myeloproliferative Disorders | 1 | Withdrawn | Dec 29, 2022 | 0 |
How it is read
Names in the registry
- “Flonoltinib 75mg”, 3 entries
- “Flonoltinib 100mg”, 2 entries
- “flonoltinib 25mg”, 2 entries
- “flonoltinib 50mg”, 2 entries
- “flonoltinib 100mg”, 2 entries
Conditions, from the studies’ own filings
- Myeloproliferative Disorders, 2 studies
- Polycythemia Vera, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.